PLEKHM2: A Potential Drug Target and Biomarker for Stroke and other Cerebrovascular Diseases

Target Name: PLEKHM2

NCBI ID: G23207

PLEKHM2

PLEKHM2: A Potential Drug Target and Biomarker for Stroke and other Cerebrovascular Diseases

Stroke is a leading cause of death and disability worldwide, affecting an estimated 170 million people each year. The most common type of stroke is ischemic stroke, which occurs when the blood flow to the brain is blocked or reduced, leading to cell death and potential brain damage. In addition to ischemic stroke, there is also a type of stroke called hemorrhagic stroke, which occurs when blood collects in the brain and causes damage.

While there are several treatments available for stroke, the availability of effective drugs and the high risk of recurrence make stroke a challenging treatment environment. Therefore, it is important to identify potential drug targets and biomarkers for stroke that can help improve treatment outcomes.

One potential drug target for stroke is PLEKHM2, a protein that is expressed in the brain and has been shown to play a role in the development and progression of both ischemic and hemorrhagic stroke. PLEKHM2 is a member of the SifA family, which includes several other proteins that have been implicated in stroke disease, including PLEKHM1, PLEKHM3, and PLEKHM4.

SifA proteins are known for their ability to interact with various proteins, including kinesins, which are proteins that help keep cells moving and maintain proper muscle and bone structure. Kinesins have been shown to play a role in the development of stroke by causing changes in the blood-brain barrier, which is the thin layer of cells that separates the brain from the surrounding blood vessels.

In addition to its role in stroke, PLEKHM2 has also been shown to have potential as a biomarker for stroke. By analyzing the expression of PLEKHM2 in stroke tissues and fluids, researchers have been able to detect the disease at an early stage and track its progression over time. This has the potential to improve treatment outcomes by allowing for earlier intervention and potentially detecting the disease at an earlier stage.

While further research is needed to fully understand the role of PLEKHM2 in stroke, its potential as a drug target and biomarker is an exciting area of research that could lead to new and more effective treatments for this debilitating disease.

Protein Name: Pleckstrin Homology And RUN Domain Containing M2

Functions: Plays a role in lysosomes movement and localization at the cell periphery acting as an effector of ARL8B. Required for ARL8B to exert its effects on lysosome location, recruits kinesin-1 to lysosomes and hence direct their movement toward microtubule plus ends. Binding to ARL8B provides a link from lysosomal membranes to plus-end-directed motility (PubMed:28325809, PubMed:22172677, PubMed:25898167, PubMed:24088571). Critical factor involved in NK cell-mediated cytotoxicity. Drives the polarization of cytolytic granules and microtubule-organizing centers (MTOCs) toward the immune synapse between effector NK lymphocytes and target cells (PubMed:24088571). Required for maintenance of the Golgi apparatus organization (PubMed:22172677). May play a role in membrane tubulation (PubMed:15905402)

The "PLEKHM2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PLEKHM2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets